{"groups":[{"description":"Subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) without systemic disease will receive acalabrutinib until disease progression or unacceptable toxicity.","id":"FG000","title":"Open-label, Single-arm"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Ten eligible participants received study treatment between 10/15/2020 and 5/6/2025."}